Targeting phosphatidylserine in anti-cancer therapy

Current Pharmaceutical Design

Volumn 15, Issue 23, 2009, Pages 2719-2723

  Kenis, Heidi ^a   Reutelingsperger, Chris ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LIPOCORTIN 5; PHOSPHATIDYLSERINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BINDING SITE; CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG PROTEIN BINDING; DRUG TARGETING; GENE EXPRESSION; GENE FUNCTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; TARGET CELL DESTRUCTION;

ANIMALS; ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL MARKERS; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PHOSPHATIDYLSERINES;

EID: 70350151198     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788923903     Document Type: Review

References (73)

1. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006; 66: 6732-40.
2. Mamot C, Ritschard R, Kung W, Park JW, Herrmann R, Rochlitz CF. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. J Drug Target 2006; 14: 215-23.
3. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, et al. Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002; 8: 1172-81.
4. Park JW, Benz CC. and Martin FJ. Future directions of liposomeand immunoliposome-based cancer therapeutics. Semin Oncol 2004; 31: 196-205.
5. Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, Gunaseelan S, et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci USA 2005; 102: 12962-7.
6. Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, Marimpietri D. Targeting liposomal chemotherapy via both tumor cellspecific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 2006; 66: 10073-82.
7. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS. Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005; 338: 284-93.
8. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 2004; 56: 1177-92.
9. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006; 103: 6315-20.
10. Kenis H, van Genderen H, Bennaghmouch A, Rinia HA, Frederik P, Narula J, et al. Cell surface-expressed phosphatidylserine and annexin A5 open a novel portal of cell entry. J Biol Chem 2004; 279: 52623-9.
11. Ran S, Thorpe PE. Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys 2002; 54: 1479-84.
12. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89: 1121-32.
13. Balasubramanian K, Schroit AJ. Aminophospholipid asymmetry: A matter of life and death. Annu Rev Physiol 2003; 65: 701-34.
14. Darland-Ransom M, Wang X, Sun CL, Mapes J, Gengyo-Ando K, Mitani S, et al. Role of C. elegans TAT-1 protein in maintaining plasma membrane phosphatidylserine asymmetry. Science 2008; 320: 528-31.
15. Yeung T, Gilbert GE, Shi J, Silvius J, Kapus A, Grinstein S. Membrane phosphatidylserine regulates surface charge and protein localization. Science 2008; 319: 210-3.
16. Martinez MC, Martin S, Toti F, Fressinaud E, Dachary-Prigent J, Meyer D, et al. Significance of capacitative Ca2+ entry in the regulation of hosphatidylserine expression at the surface of stimulated cells. Biochemistry 1999; 38: 10092-8.
17. Denecker G, Dooms H, Van Loo G, Vercammen D, Grooten J, Fiers W, et al. Phosphatidyl serine exposure during apoptosis precedes release of cytochrome c and decrease in mitochondrial transmembrane potential. FEBS Lett 2000; 465: 47-52.
18. Verhoven B, Krahling S, Schlegel RA, Williamson P. Regulation of phosphatidylserine exposure and phagocytosis of apoptotic T lymphocytes. Cell Death Differ 1999; 6: 262-70.
19. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992; 148: 2207-16.
20. Bratton DL, Fadok VA, Richter DA, Kailey JM, Guthrie LA, Henson PM. Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase. J Biol Chem 1997; 272: 26159-65.
21. Verhoven B, Schlegel RA, Williamson P. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J Exp Med 1995; 182: 1597-601.
22. Williamson P, Bevers EM, Smeets EF, Comfurius P, Schlegel RA, Zwaal RF. Continuous analysis of the mechanism of activated transbilayer lipid movement in platelets. Biochemistry 1995; 34: 10448-55.
23. Sahu SK, Gummadi SN, Manoj N, Aradhyam GK. Phospholipid scramblases: An overview. Arch Biochem Biophys 2007; 462: 103-14.
24. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995; 184: 39-51.
25. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995; 182: 1545-56.
26. Leist M, Jaattela M. Four deaths and a funeral: From caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001; 2: 589-98.
27. Corsten MF, Hofstra L, Narula J, Reutelingsperger CP. Counting heads in the war against cancer: Defining the role of annexin A5 imaging in cancer treatment and surveillance. Cancer Res 2006; 66: 1255-60.
28. Callahan MK, Halleck MS, Krahling S, Henderson AJ, Williamson P, Schlegel RA. Phosphatidylserine expression and phagocytosis of apoptotic thymocytes during differentiation of monocytic cells. J Leukoc Biol 2003; 74: 846-56.
29. Elliott JI, Surprenant A, Marelli-Berg FM, Cooper JC, Cassady- Cain RL, Wooding C, et al. Membrane phosphatidylserine distribution as a non-apoptotic signalling mechanism in lymphocytes. Nat Cell Biol 2005; 7: 808-16.
30. Dias-Baruffi M, Zhu H, Cho M, Karmakar S, McEver RP, Cummings RD. Dimeric galectin-1 induces surface exposure of phosphatidylserine and phagocytic recognition of leukocytes without inducing apoptosis. J Biol Chem 2003; 278: 41282-93.
31. Stowell SR, Karmakar S, Stowell CJ, Dias-Baruffi M, McEver RP, Cummings RD. Human galectin-1, -2, and -4 induce surface exposure of phosphatidylserine in activated human neutrophils but not in activated T cells. Blood 2007; 109: 219-27.
32. Lyden TW, Ng AK, Rote NS. Modulation of phosphatidylserine epitope expression by BeWo cells during forskolin treatment. Placenta 1993; 14: 177-86.
33. Rote NS, Chang J, Katsuragawa H, Ng AK, Lyden TW, Mori T. Expression of phosphatidylserine-dependent antigens on the surface of differentiating BeWo human choriocarcinoma cells. Am J Reprod Immunol 1995; 33: 114-21.
34. van den Eijnde SM, van den Hoff MJ, Reutelingsperger CP, van Heerde WL, Henfling ME, Vermeij-Keers C, et al. Transient expression of phosphatidylserine at cell-cell contact areas is required for myotube formation. J Cell Sci 2001; 114: 3631-42.
35. Dillon SR, Constantinescu A, Schlissel MS. Annexin V binds to positively selected B cells. J Immunol 2001; 166: 58-71.
36. Elliott JI, Sardini A, Cooper JC, Alexander DR, Davanture S, Chimini G, et al. Phosphatidylserine exposure in B lymphocytes: A role for lipid packing. Blood 2006; 108: 1611-7.
37. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 2002; 62: 6132-40
38. Zullig S, Neukomm LJ, Jovanovic M, Charette SJ, Lyssenko NN, Halleck MS, et al. Aminophospholipid translocase TAT-1 promotes phosphatidylserine exposure during C. elegans apoptosis. Curr Biol 2007; 17: 994-9.
39. Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002; 2: 965-75.
40. Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S. Identification of Tim4 as a phosphatidylserine receptor. Nature 2007; 450: 435-9.
41. Munoz LE, Frey B, Pausch F, Baum W, Mueller RB, Brachvogel B, et al. The role of annexin A5 in the modulation of the immune response against dying and dead cells. Curr Med Chem 2007; 14: 271-7.
42. Kenis H, van Genderen H, Deckers NM, Lux PA, Hofstra L, Narula J, et al. Annexin A5 inhibits engulfment through internalization of PS-expressing cell membrane patches. Exp Cell Res 2006; 312(6): 719-26.
43. Munoz LE, Franz S, Pausch F, Furnrohr B, Sheriff A, Vogt B, et al. The influence on the immunomodulatory effects of dying and dead cells of Annexin V. J Leukoc Biol 2007; 81: 6-14.
44. Frey B, Munoz LE, Pausch F, Sieber R, Franz S, Brachvogel B, et al. The immune reaction against allogeneic necrotic cells is reduced in AnnexinA5 knock out mice whose macrophages display an antiinflammatory phenotype. J Cell Mol Med 2008; [Epub ahead of print].
45. Gaipl US, Beyer TD, Baumann I, Voll RE, Stach CM, Heyder P, et al. Exposure of anionic phospholipids serves as anti-inflammatory and immunosuppressive signal - implications for antiphospholipid syndrome and systemic lupus erythematosus. Immunobiology 2003; 207: 73-81.
46. Stach CM, Turnay X, Voll RE, Kern PM, Kolowos W, Beyer TD, et al. Treatment with annexin V increases immunogenicity of apoptotic human T-cells in Balb/c mice. Cell Death Differ 2000; 7: 911-5.
47. Bondanza A, Zimmermann VS, Rovere-Querini P, Turnay J, Dumitriu IE, Stach CM, et al. Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. J Exp Med 2004; 200: 1157-65.
48. van Genderen HO, Kenis H, Hofstra L, Narula J, Reutelingsperger CP. Extracellular annexin A5: Functions of phosphatidylserinebinding and two-dimensional crystallization. Biochim Biophys Acta 2008; 1783: 953-63.
49. Reutelingsperger CP, Hornstra G, Hemker HC. Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord. Eur J Biochem 1985 151: 625-9.
50. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-20
51. Boersma HH, Kietselaer BL, Stolk LM, Bennaghmouch A, Hofstra L, Narula J, et al. Past, present, and future of annexin A5: From protein discovery to clinical applications. J Nucl Med 2005; 46: 2035-50.
52. van den Eijnde SM, Boshart L, Reutelingsperger CPM, De Zeeuw CI, Vermeij-Keers C. Phosphatidylserine plasma membrane asymmetry in vivo: A pancellular phenomenon which alters during apoptosis. Cell Death Differ 1997; 4: 311-316.
53. Dumont EA, Reutelingsperger CP, Smits JF, Daemen MJ, Doevendans PA, Wellens HJ, et al. Real-time imaging of apoptotic cellmembrane changes at the single-cell level in the beating murine heart. Nat Med 2001; 7: 1352-5.
54. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA 1998; 95: 6349-54.
55. Ntziachristos V, Schellenberger EA, Ripoll J, Yessayan D, Graves E, Bogdanov A, et al. Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin VCy5.5 conjugate. Proc Natl Acad Sci USA 2004; 101: 12294-9.
56. Hofstra L, Liem IH, Dumont EA, Boersma HH, van Heerde WL, Doevendans PA, et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 2000; 356: 209-12.
57. Hofstra L, Dumont EA, Thimister PW, Heidendal GA, DeBruine AP, Elenbaas TW, et al. In vivo detection of apoptosis in an intracardiac tumor. JAMA 2001; 285: 1841-2.
58. Narula J, Acio ER, Narula N, Samuels LE, Fyfe B, Wood D, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med 2001; 7: 1347-52.
59. Kietselaer BL, Reutelingsperger CP, Heidendal GA, Daemen MJ, Mess WH, Hofstra L, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotidartery atherosclerosis. N Engl J Med 2004; 350: 1472-3.
60. Belhocine TZ, Blankenberg FG. 99mTc-Annexin A5 uptake and imaging to monitor chemosensitivity. Methods Mol Med 2005; 111: 363-80.
61. Rottey S, Slegers G, Van Belle S, Goethals I, Van de Wiele C. Sequential 99mTc-hydrazinonicotinamide-annexin V imaging for predicting response to chemotherapy. J Nucl Med 2006; 47: 1813-8.
62. Kartachova M, van Zandwijk N, Burgers S, van Tinteren H, Verheij M, Valdes Olmos RA. Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. J Clin Oncol 2007; 25: 2534-9.
63. Jennewein M, Lewis MA, Zhao D, Tsyganov E, Slavine N, He J, et al. Vascular imaging of solid tumors in rats with a radioactive arsenic- labeled antibody that binds exposed phosphatidylserine. Clin. Cancer Res 2008; 14: 1377-85.
64. Kenis H, Hofstra L, Reutelingsperger CP. Annexin A5: Shifting from a diagnostic towards a therapeutic realm. Cell Mol Life Sci 2007; 64: 2859-62.
65. Huang X, Bennett M, Thorpe PE. A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. Cancer Res 2005; 65: 4408-16.
66. Luster TA, He J, Huang X, Maiti SN, Schroit AJ, de Groot PG, et al. Plasma protein beta-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells. J Biol Chem 2006; 281: 29863-71.
67. Willems GM, Janssen MP, Comfurius P, Galli M, Zwaal RF, Bevers EM. Competition of annexin V and anticardiolipin antibodies for binding to phosphatidylserine containing membranes. Biochemistry 2000; 39: 1982-9.
68. Tait JF, Engelhardt S, Smith C, Fujikawa K. Prourokinase-annexin V chimeras. Construction, expression, and characterization of recombinant proteins. J Biol Chem 1995; 270: 21594-9.
69. Tanaka K, Einaga K, Tsuchiyama H, Tait JF, Fujikawa K. Preparation and characterization of a disulfide-linked bioconjugate of annexin V with the B-chain of urokinase: An improved fibrinolytic agent targeted to phospholipid-containing thrombi. Biochemistry 1996; 35: 922-9.
70. Prinzen L, Miserus RJ, Dirksen A, Hackeng TM, Deckers N, Bitsch NJ, et al. Optical and magnetic resonance imaging of cell death and platelet activation using annexin a5-functionalized quantum dots. Nano Lett 2007; 7: 93-100.
71. Ballarin L, Burighel P, Cima F. A tale of death and life: Natural apoptosis in the colonial ascidian Botryllus schlosseri (Urochordata, Ascidiacea). Curr Pharm Des 2008; 14(2): 138-47.
72. Blankenberg FG. Monitoring of treatment-induced apoptosis in oncology with PET and SPECT. Curr Pharm Des 2008; 14(28): 2974-82.
73. Matarrese P, Ciarlo L, Tinari A, Piacentini M, Malorni W. Xeno-cannibalism as an exacerbation of self-cannibalism: A possible fruitful survival strategy for cancer cells. Curr Pharm Des 2008; 14(3): 245-52.